Global Dandy-Walker Treatment Market, By Type (Isolated Cerebellar Vermis Hypoplasia, Mega-Cisterna Magna, Posterior Fossa Arachnoid Cyst), Treatment (Surgical Implantation of Shunt in Skull, Multiple Therapies), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Dandy-Walker Treatment Market Analysis and Size
The Dandy-Walker treatment market is projected to witness significant growth in the forecast period. The market for dandy-walker syndrome treatment is assessed to expand significantly during the forecast period because of the increasing prevalence of brain disorders, growing prevalence of the diseases that boost cerebral infarction, extensive R&D practices, rising awareness and medical expenditure of the global population, and technological advancements.
Data Bridge Market Research analyses a growth rate in the Dandy-Walker treatment market in the forecast period 2023-2030. The expected CAGR of Dandy-Walker treatment market is tend to be around 3.50% in the mentioned forecast period. The market was valued at USD 30.37 billion in 2022, and it would grow upto USD 40 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Dandy-Walker Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Isolated Cerebellar Vermis Hypoplasia, Mega-Cisterna Magna, Posterior Fossa Arachnoid Cyst), Treatment (Surgical Implantation of Shunt in Skull, Multiple Therapies), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Johnson & Johnson Services, Inc. (U.S.), CHRISTOPH MIETHKE GMBH & CO. KG (Germany), Integra LifeSciences (U.S.), Abbvie,Inc (U.S)
|
|
Market Opportunities
|
|
Market Definition
Dandy-Walker syndrome is the combination of a bunch of disorders that affect brain development. Cerebellar vermis portion of the brain is expected to be smaller (hypoplastic) or may be absent (aplastic), which is said to be occurred in Dandy-Walker patient. Larger than expected, the increased size of the fourth ventricle of Cerebellar vermis can be seen in people who are affected by Dandy-Walker. This ventricle allows fluid to flow between the upper and lower areas of the brain and spinal cord. The larger size of the skull can be identified in Dandy-Walker affected patients. It is more common in females than in males.
Global Dandy-Walker Treatment Market Dynamics
Drivers
- Increase in Neurological Disorders
The geriatric population is expected to increase the patient population globally, which boots the Dandy-Walker treatment market in the forecast period. Neurological disorders is the second leading cause of death after heart disease and with 276 million and 11·6% of global deaths, it is the leading cause of disability. The frequency of 1 per 25000-35000 affected by Dandy-Walker malformations in the U.S. is more common in females than males. Therefore, Dandy-Walker treatment market has been growing more significantly, especially in the North America region. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is projected to increase the market growth. The segment is estimated to accelerate the market as most products are available in capsule form and tablet form and it is a very convenient route of administration.
Opportunities
- Higher Demand of Hospitals
The increasing demand of hospitals rise the market growth significantly. Most neurological disorders diagnostics are mostly carried out in hospitals as they are very complex in nature and it requires technologically advanced equipment and thus this is driving the market for hospital or clinical laboratories.
- Strategic Alliances
Vendors are concentrating on addressing the issues related with the high cost of R&D activities of therapeutic drugs by collaborating with pharmaceutical companies. They also increase their distribution networks through numerous strategic alliances with other vendors. Consequently, developing and commercializing of advanced therapies and drugs for neurological disorders is rising. This development is estimated to have a high impact on the market growth. This boost the market growth.
Restraints/Challenges
- Inadequate Information in anesthesia-related coverings
The major challenge for dandy-walker treatment market is that even though it is well discussed in pediatric literature but found absent in anesthesia-related coverings. As this syndrome involves anesthesia while conducting surgery because 80% of the cases will develop hydrocephalus and requires surgery, it has been seen the physical transformations are affected more.
- High Cost
The huge expenditure of treatment methods hamper the market growth. The treatment includes costly surgeries and several other therapies limiting the market's growth.
This Dandy-Walker treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Dandy-Walker treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Dandy-Walker Treatment Market Scope
The Dandy-Walker treatment market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Isolated Cerebellar Vermis Hypoplasia
- Mega-Cisterna Magna
- Posterior Fossa Arachnoid Cyst
Treatment
- Surgical Implantation of Shunt in Skull
- Multiple Therapies
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Dandy-Walker Treatment Market Regional Analysis/Insights
The Dandy-Walker treatment market is analyzed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the Dandy-Walker treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to enhanced government support for research purposes and a rise in awareness about brain disorders in these regions.
North America dominates the market due to innovative healthcare solutions and advanced healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Dandy-Walker Treatment Market Share Analysis
The Dandy-Walker treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Dandy-Walker treatment market.
Key players operating in the Dandy-Walker treatment market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (U.K.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Johnson & Johnson Services, Inc. (U.S.)
- CHRISTOPH MIETHKE GMBH & CO. KG (Germany)
- Integra LifeSciences (U.S.)
- Abbvie,Inc (U.S)
SKU-